Page last updated: 2024-11-04

tartaric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

tartaric acid: RN given refers to cpd with unspecified isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

D-tartaric acid : The D-enantiomer of tartaric acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID444305
CHEMBL ID1236315
CHEBI ID15671
CHEBI ID26849
SCHEMBL ID5762
MeSH IDM0094762
PubMed CID439655
CHEMBL ID1200861
CHEBI ID15672
SCHEMBL ID116846
MeSH IDM0094762

Synonyms (273)

Synonym
e-334
CHEMBL1236315
ins no.334
e 334
ins-334
rechtsweinsaeure
weinsteinsaeure
(2r,3r)-2,3-dihydroxybernsteinsaeure
(+)-(r,r)-tartaric acid
(+)-weinsaeure
CHEBI:15671 ,
(2r,3r)-2,3-dihydroxysuccinic acid
l-threaric acid
(+)-l-tartaric acid
(1r,2r)-1,2-dihydroxyethane-1,2-dicarboxylic acid
(2r,3r)-2,3-dihydroxybutanedioic acid
tartaric acid, l-(+)-
(r,r)-(+)-tartaric acid
nsc-62778
natural tartaric acid
l-(+)-tartaric acid
(+)-(2r,3r)-tartaric acid
threaric acid
dextrotartaric acid
tartaric acid (jp17/nf)
D00103
tartaric acid (tn)
einecs 201-766-0
kyselina vinna [czech]
butanedioic acid, 2,3-dihydroxy- (2r,3r)-
(2r,3r)-(+)-tartaric acid
tartaric acid [usan:jan]
acidum tartaricum
ai3-06298
tartaric acid; l-(+)-tartaric acid
butanedioic acid, 2,3-dihydroxy- (r-(r*,r*))-
nsc 62778
1,2-dihydroxyethane-1,2-dicarboxylic acid
succinic acid, 2,3-dihydroxy
d-alpha,beta-dihydroxysuccinic acid
butanedioic acid, 2,3-dihydroxy-; butanedioic acid, 2,3-dihydroxy-, (r-(r*,r*))-
kyselina 2,3-dihydroxybutandiova [czech]
tartaric acid (van)
tartaric acid, l-
C00898
l-tartaric acid
(+)-tartaric acid
87-69-4
(r,r)-tartaric acid
l(+)-tartaric acid
tartaric acid d,l
nsc-148314
resolvable tartaric acid
l-(+)-tartaric acid, >=99.7%, fcc, fg
l-(+)-tartaric acid, bioxtra
1D5R
l-(+)-tartaric acid, acs reagent, >=99.5%
(+-)-tartaric acid
butanedioic acid, 2,3-dihydroxy-, (r*,r*)-
ccris 8978
nsc 148314
butanedioic acid, 2,3-dihydroxy-, (r*,r*)-(+-)-
butanedioic acid, 2,3-dihydroxy-, (theta,theta)-(+-)-
(2rs,3rs)-tartaric acid
fema no. 3044
einecs 205-105-7
smr000112492
MLS001336057
l-(+)-tartaric acid, >=99.5%
l-(+)-tartaric acid, bioultra, >=99.5% (t)
000189E3-11D0-4B0A-8C7B-31E02A48A51F
l-2,3-dihydroxybutanedioic acid
(r,r)-tartarate
T0025
NCGC00247911-01
cas-87-69-4
tox21_300155
dtxsid8023632 ,
dtxcid203632
NCGC00254043-01
nsc759609
pharmakon1600-01300044
nsc-759609
HMS2270G22
ec 201-766-0
kyselina vinna
unii-w4888i119h
kyselina 2,3-dihydroxybutandiova
w4888i119h ,
4j4z8788n8 ,
unii-4j4z8788n8
144814-09-5
(2r,3r)-rel-2,3-dihydroxysuccinic acid
tartaric acid [vandf]
tartaric acid [orange book]
tartaricum acidum
tartaric acid [mart.]
tartaric acid [ep monograph]
tartaric acid [inci]
tartaric acid component of baros
tartaricum acidum [hpus]
tartaric acid [who-dd]
tartaric acid (l(+)-)
tartaric acid [fcc]
butanedioic acid, 2,3-dihydroxy-, (r-(r*,r*))-
tartaric acid [jan]
tartaric acid [ii]
l-2,3-dihydroxysuccinic acid
l-tartaric acid [mi]
baros component tartaric acid
tartaric acid [usp-rs]
4EBT
S6233
tartaric acid, dl-
tartaric acid, dl- [ii]
dl-tartaric acid [mi]
tartaric acid,dl-
tartaric acid,dl- [vandf]
tartaric acid, (+/-)-
rel-(2r,3r)-2,3-dihydroxybutanedioic acid
BP-31012
SCHEMBL5762
J-500964
l-(+)-tartaric acid, acs
l-threaric aci
l(+) tartaric acid
(2r,3r)-2,3-dihydroxy-succinic acid
l(+)tartaric acid
l-(+) tartaric acid
AKOS016843282
STR02377
F8880-9012
mfcd00064207
J-520420
l-(+)-tartaric acid, reagentplus(r), >=99.5%
l-(+)-tartaric acid, anhydrous, free-flowing, redi-dri(tm), acs reagent, >=99.5%
l-(+)-tartaric acid, tested according to ph.eur.
l-(+)-tartaric acid, puriss. p.a., acs reagent, >=99.5%
l-(+)-tartaric acid, saj first grade, >=99.5%
l-(+)-tartaric acid, certified reference material, tracecert(r)
l-(+)-tartaric acid, jis special grade, >=99.5%
tartaric acid, united states pharmacopeia (usp) reference standard
D70248
l-(+)-tartaric acid, p.a., acs reagent, reag. iso, reag. ph. eur., 99.5%
tartaric acid, pharmaceutical secondary standard; certified reference material
l-(+)-tartaric acid, p.a., acs reagent, 99.0%
l-(+)-tartaric acid, natural, >=99.7%, fcc, fg
l-(+)-tartaric acid, ar, >=99%
l-(+)-tartaric acid, vetec(tm) reagent grade, 99%
weinsaure
SBI-0207063.P001
(+)-tartarate
d-a,b-dihydroxysuccinic acid
2,3-dihydroxy-succinate
(2r,3r)-tartarate
(2r,3r)-2,3-tartaric acid
DB09459
2,3-dihydroxy-succinic acid
CS-W020107
HY-Y0293
138508-61-9
dl tartaric acid
Q18226455
tartaric-acid
lamb protein (fungal)
132517-61-4
(2r,3r)-2,3-dihydroxysuccinicacid
EN300-72271
tartaric acid (mart.)
tartaric acid (ii)
traubensaeure
tartaric acid (usp-rs)
(r*,r*)-(+-)-2,3-dihydroxybutanedioic acid
(r*,r*)-2,3-dihydroxybutanedioic acid
chebi:26849
para-weinsaeure
acide tartrique
tartaric acid (ep monograph)
(2r,3r)-rel-2,3-dihydroxybutanedioic acid
acido tartarico
vogesensaeure
Z1147451717
rr-tartaric acid
d-(-)-tartaric acid
(-)-weinsaeure
(2s,3s)-(-)-tartaric acid
d-threaric acid
CHEBI:15672 ,
(s,s)-(-)-tartaric acid
d(-)-tartaric acid
(2s,3s)-2,3-dihydroxybutanedioic acid
(-)-(s,s)-tartaric acid
(-)-d-tartaric acid
linksweinsaeure
NCGC00014424
C02107
d-tartaric acid
(-)-tartaric acid
(2s,3s)-tartaric acid
147-71-7
tartaric acid
(s,s)-tartaric acid
dl-tartaric acid
d-(-)-tartaric acid, 99%
d-(-)-tartaric acid, reagentplus(r), 99%
dl-tartaric acid, reagentplus(r), 99%
DB01694
1RPA
NCI155080
c4h6o6
NCISTRUC2_000222
NCISTRUC1_000172
NCGC00097529-01
MLS001076664
d-()-tartaric acid
smr000499572
e334
CHEMBL1200861
AKOS005067832
T0026
A22830
(s,s)-tartaric acid;tartaric acid;d-(-)-tartaric acid
dtxsid5046986 ,
HMS2231C23
CCG-38066
NCGC00014424-02
butanedioic acid, 2,3-dihydroxy-, (s-(r*,r*))-
unii-rrx6a4pl3c
butanedioic acid, 2,3-dihydroxy-, (s-(theta,theta))-
levo-tartaric acid
rrx6a4pl3c ,
einecs 205-695-6
tartaric acid, d-(-)-
butanedioic acid, 2,3-dihydroxy-, (2s,3s)-
BP-13000
AM20080237
(2s,3s)-2,3-dihydroxysuccinic acid
unnatural tartaric acid
d-tartaric acid [mi]
tartaric acid, d-
unusual tartaric acid
S3134
(+/-)-tartaric acid
BP-31023
SCHEMBL116846
J-501029
DTXSID4043775
(2s,3s) (-) tartaric acid
(2s, 3s)-tartaric acid
FEWJPZIEWOKRBE-LWMBPPNESA-N
levo tartaric acid
(+)-d-tartaric acid
d-(-)-tartaricacid
mfcd00071626
mfcd00004238
d-(-)-tartaric acid, puriss., unnatural form, >=99.0% (t)
dl-tartaric acid, anhydrous, for ion chromatography, >=99.5% (t)
D78024
d-(-)-tartaric acid, vetec(tm) reagent grade, 99%
dl-tartaric acid, vetec(tm) reagent grade, 99%
dl-tartaric acid, >=99%
d-(-)-tartaric acid, lr, >=98%
J-006363
CS-0017144
1007601-97-9
e-7050 (2s,3s)-2,3-dihydroxysuccinic acid
DS-3383
106449-07-4
Q23034947
(2r/s,3r/s)-dihydroxy-1,4-butanedioic acid
s-bacampicillin
EN300-72270
Z1147451575

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Even the therapeutic use of aluminum phosphate is not expected to be totally safe in the presence of tartaric acid."( Aluminum speciation studies in biological fluids. Part 6. Quantitative investigation of aluminum(III)-tartrate complex equilibria and their potential implications for aluminum metabolism and toxicity.
Berthon, G; Daydé, S; Desroches, S, 2000
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" The area under the plasma concentration-time curve (AUC), mean residence time (MRT), systemic clearance (CL), distribution volume at steady state (V(ss)) and terminal plasma half-life (T(1/2,beta)) of nicotine were compared between NB and NS."( Different pharmacokinetics of nicotine following intravenous administration of nicotine base and nicotine hydrogen tartarate in rats.
Chul Chung, B; Chung, SJ; Hwa Jung, B; Shim, CK, 2001
)
0.31

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of potassium from orally administered potassium tartrate was evaluated in 20 normal subjects under metabolic balance conditions."( In vitro and in vivo assessment of the bioavailability of potassium from a potassium tartrate tablet.
Gorecki, DK; Jones, D; Whiting, SJ, 1991
)
0.28
"The bioavailability of bumetanide following the oral administration of tablets, or the rectal administration of either macrogol suppositories or suppositories with and without weak acids were evaluated in human subjects."( Bioavailability and diuretic effect of bumetanide following rectal administration of suppositories containing weak acids in human subjects.
Kenmotsu, H; Oda, K; Sekikawa, H; Shimode, Y; Takada, M; Yagi, N, 1993
)
0.29
" The bioavailability (absolute), expressed as the ratio of the area under the plasma concentration-time curve (AUC) following oral administration of bumetanide, was 39% that of intravenous administration."( Enhanced absorption of bumetanide from suppositories containing weak acids in rabbits.
Kenmotsu, H; Oda, K; Sekikawa, H; Shimode, Y; Takada, M; Yagi, N, 1993
)
0.29
" Our results suggested that low molecular weight polyphenols are absorbed in the intestine and metabolized to their glucuronide conjugates, which exhibit antioxidative activity in plasma, and that TA can enhance the bioavailability of wine polyphenols."( Absorption and metabolism of antioxidative polyphenolic compounds in red wine.
Harada, M; Kiso, Y; Koda, H; Sakane, T; Sezaki, H; Sugiura, N; Yamashita, S, 2002
)
0.31
" The results may be important for elucidating factors affecting iron bioavailability in the small intestine and for the development of foods with improved iron bioavailability."( Organic acids influence iron uptake in the human epithelial cell line Caco-2.
Andlid, T; Salovaara, S; Sandberg, AS, 2002
)
0.31
" No marked changes in the in vivo absorption rate (t(max)) were noted, but the amounts of furosemide absorbed (AUC(0- infinity ) and C(max)) decreased as the in vitro release rate decreased, although this was not statistically significant in the case of AUC."( Evaluation of microcrystalline chitosans for gastro-retentive drug delivery.
Jürjenson, H; Marvola, M; Säkkinen, M; Tuononen, T; Veski, P, 2003
)
0.32
"This study was undertaken to investigate the bioavailability of various L-carnitine esters (acetyl-L-carnitine and lauroyl-L-carnitine) and salts (L-carnitine L-tartrate, L-carnitine fumarate, L-carnitine magnesium citrate) relative to base of free L-carnitine."( Free and total carnitine concentrations in pig plasma after oral ingestion of various L-carnitine compounds.
Becker, K; Eder, K; Felgner, J; Kluge, H, 2005
)
0.33
" The results of the study indicate that CPLX shows improved dissolution properties and a higher relative oral bioavailability compared with PHYS and MICO."( Oral bioavailability in pigs of a miconazole/hydroxypropyl-gamma-cyclodextrin/L-tartaric acid inclusion complex produced by supercritical carbon dioxide processing.
Barillaro, V; Delattre, L; Evrard, B; Piell, G, 2005
)
0.33
"The effect of co-administration of a mucolytic agent with a penetration enhancer was assessed on the intestinal absorption of poorly absorbed hydrophilic compounds."( Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant.
Horikiri, Y; Kitazawa, T; Morita, T; Takatsuka, S; Yoshino, H, 2006
)
0.33
"The investigation was undertaken with the objective of comparing two in vitro techniques, measuring dialyzable iron (method A) and measuring ionizable iron (method B), for iron bioavailability in a model system."( Comparative analysis of influence of promoters and inhibitors on in vitro available iron using two methods.
Gupta, S; Jyothi Lakshmi, A; Prakash, J,
)
0.13
" The addition of citric acid (80 mg/100 g) along with ferrous sulfate increased bioavailability by about 104% over that in controls."( In vitro bioavailability of iron and sensory qualities of iron-fortified wheat biscuits.
Govindaraj, T; KrishnaRau, L; Prakash, J, 2007
)
0.34
"From both the subjective and the objective evaluation of biscuits, it can be concluded that the addition of NaFeEDTA along with either citric acid (80 mg/100 g) or tartaric acid (100 mg/100 g) results in improved iron bioavailability with an organoleptically acceptable product."( In vitro bioavailability of iron and sensory qualities of iron-fortified wheat biscuits.
Govindaraj, T; KrishnaRau, L; Prakash, J, 2007
)
0.34
" Metal bioavailability in soil at the end of the experiment was higher in the trials treated with EDTA than in those treated with tartrate and glutamate, the latter not being significantly different from the control."( Heavy metal distribution between contaminated soil and Paulownia tomentosa, in a pilot-scale assisted phytoremediation study: influence of different complexing agents.
Azzarello, E; Checchini, L; Del Bubba, M; Doumett, S; Lamperi, L; Mancuso, S; Mugnai, S; Petruzzelli, G, 2008
)
0.35
" Insoluble fibers are poorly absorbed and are known to improve fecal bulk and laxation and ameliorate constipation."( A review of dietary fiber and health: focus on raisins.
Bell, SJ, 2011
)
0.37
"Decontamination of polluted soils using plants is based on the ability of plant species (including transgenic plants) to enhance bioavailability of pollutants in the rhizosphere and support growth of pollutant-degrading microorganisms via root exudation and plant species-specific composition of the exudates."( Natural occurrence of enantiomers of organic compounds versus phytoremediations: should research on phytoremediations be revisited? A mini-review.
Formánek, P; Lojková, L; Rejšek, K; Vranová, V, 2014
)
0.4
"The purpose of this study was to develop a new delivery system based on drug cyclodextrin (CD) complexation and loading into nanostructured lipid carriers (NLC) to improve the oral bioavailability of vinpocetine (VP)."( A novel oral delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for poorly water-soluble drug: vinpocetine.
Chen, F; Lin, C; Liu, D; Pan, W; Xiong, W; Yang, X; Ye, T; Zhang, L; Zhang, W, 2014
)
0.4
" The granules containing citric acid (KZ/CA granule) improved the dissolution of KZ after oral administration to rats under low gastric acid conditions, where the bioavailability of the KZ/CA granules at elevated gastric pH was comparable with that of KZ only at gastric acidic pH."( Improved dissolution and absorption of ketoconazole in the presence of organic acids as pH-modifiers.
Adachi, M; Hinatsu, Y; Katsumi, H; Kusamori, K; Nakatani, M; Sakane, T; Wada, K; Yamamoto, A, 2015
)
0.42
" While all three acids elevated the bioavailability of mercury, which increased with the increase of the concentration of acids."( [Effect of Low Molecular Weight Organic Acids on the Chemical Speciation and Activity of Mercury in the Soils of the Water-Level-Fluctuating Zone of the Three Gorges Reservoir].
Deng, H; Liang, L; Qin, CQ; Wang, DY; You, R, 2016
)
0.43
" Overall, LMWOAs boosted the bioavailability of Pb in purple soil and had a potential risk to contaminate underground water."( [Effects of Low-Molecular-Weight Organic Acids on the Speciation of Pb in Purple Soil and Soil Solution].
Chen, H; Huang, R; Jiang, T; Liu, J; Zhang, JZ, 2016
)
0.43
"The purpose of this study is to improve the solubility, in vitro dissolution, and oral bioavailability in rats of tadalafil (TDF) by using SD technique with a weak acid and a copolymer."( Use of acidifier and solubilizer in tadalafil solid dispersion to enhance the in vitro dissolution and oral bioavailability in rats.
Byeon, JC; Choi, JS; Jang, WS; Jeong, HM; Kwon, SH; Lee, SE; Park, JS, 2017
)
0.46
"Here, solid dispersion (SD) techniques were utilized to improve the oral bioavailability of tadalafil (TDF)."( Tadalafil solid dispersion formulations based on PVP/VA S-630: Improving oral bioavailability in rats.
Byeon, JC; Choi, JS; Jang, WS; Lee, SE; Park, JS, 2017
)
0.46
" Zoledronic acid is a class III drug with poor oral bioavailability due to its poor permeability and low aqueous solubility; hence an attempt has been made to improve its solubility by co-crystallization technology."( Designing of Stable Co-crystals of Zoledronic Acid Using Suitable Coformers.
Badamane Sathyanarayana, M; Laxmi, P; Pai, A; Pai, G; Sg, V; Varma, A, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Urinary excretion of potassium, as determined from 24-h urinary collections on the 3 days preceding dosage totalled 192."( In vitro and in vivo assessment of the bioavailability of potassium from a potassium tartrate tablet.
Gorecki, DK; Jones, D; Whiting, SJ, 1991
)
0.28
" In the solid dosage forms, influences of the additives were also studied."( [Interaction between polyethylene films and brombexine HCl in solid dosage form. II. Effects of moisture property on the sorption of the drug].
Kukita, T; Nakai, Y; Nemoto, M; Okamoto, A; Yamaguchi, A; Yamaguchi, H; Yamamoto, K, 1990
)
0.28
" On the contrary, their glass transition and flow temperatures were much higher than those of LA oligomers, indicating that their handling during the preparation of drug delivery dosage forms was much improved."( New biodegradable oligoesters for pharmaceutical application.
Hyon, SH; Ikada, Y; Wada, R, 1996
)
0.29
" Various dosing solutions containing a penetration enhancer in the absence or in the presence of NAC were directly administered into the exposed rat jejunum, and the bioavailability of FD-4 up to 2 h was determined."( Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant.
Horikiri, Y; Kitazawa, T; Morita, T; Takatsuka, S; Yoshino, H, 2006
)
0.33
" An increase of urinary excretion of riboflavin was observed when the volunteers were dosed with the floating pellets, especially after feeding."( In vitro and in vivo evaluation of floating riboflavin pellets developed using the melt pelletization process.
Amighi, K; Goole, J; Hamdani, J; Moës, AJ, 2006
)
0.33
" The reasonably high radical yields of the dl-TA in the dose range of interest, the fairly good stabilities of the species produced (I and II) at room temperature, and the almost linear features of the constructed dose-response curves led us to conclude that the intensities associated with the stable species (I and II) could be used to estimate the applied dose in the dose range of 100 Gy-34 kGy with fairly good accuracy and that dl-TA could be a good candidate for exploring low radiation dose measurements by ESR dosimetry."( Kinetic features of the radical species produced in gamma-irradiated dl-tartaric acid and the dosimetric potential of this acid.
Korkmaz, M; Tuner, H, 2009
)
0.35
" The obtained new insight into the occurring drug-polymer interactions can help to facilitate the development/optimisation of this type of dosage forms."( Characterisation of quaternary polymethacrylate films containing tartaric acid, metoprolol free base or metoprolol tartrate.
Glaessl, B; Rades, T; Siepmann, F; Siepmann, J; Tucker, I, 2009
)
0.35
" The obtained new insight into the underlying drug release mechanisms in Eudragit RL networks can help to facilitate the optimisation of this type of dosage forms."( Deeper insight into the drug release mechanisms in Eudragit RL-based delivery systems.
Glaessl, B; Rades, T; Siepmann, F; Siepmann, J; Tucker, I, 2010
)
0.36
" A power function of the radiation dose was found to describe well the dose-response curve of the central resonance signal, and adjusting the microwave power and modulation amplitude to be 2 mW and 1 mT, respectively, was found to increase the sensitivity of PT."( An electron spin resonance (ESR) investigation of the dosimetric potential of potassium tartrate.
Korkmaz, G; Ozsayin, F; Polat, M, 2012
)
0.38
" Therefore, the proposed method is suitable for the routine control of these ingredients in multicomponent dosage forms."( Capillary electrophoretic determination of antimigraine formulations containing caffeine, ergotamine, paracetamol and domperidone or metoclopramide.
Alshehri, MM; Alzoman, NZ; Elshahed, MS; Maher, HM; Olah, IV; Rizk, MS; Sultan, MA, 2013
)
0.39
"The main aim of this study was to investigate the effects of pharmaceutical technological methods on pepsin activity during the formulation of solid dosage forms."( Effects of pharmaceutical processing on pepsin activity during the formulation of solid dosage forms.
Kristó, K; Pintye-Hódi, K, 2013
)
0.39
" When tartaric acid is dosed at room temperature and immediately cooled to 100 K for imaging, individual bitartrate molecules were found."( Chemisorptive enantioselectivity of chiral epoxides on tartaric-acid modified Pd(111): three-point bonding.
Mahapatra, M; Tysoe, WT, 2015
)
0.42
"In series of pharmacometrics research by determination of an optimum model of dosing is established that introduction of OKAGERM-4 in a dose of 96."( STUDY OF PHARMACOMETRIC INDEXES OF DOSING REGIMEN OF ANTIHYPOXANT OKAGERM-4.
Kravets, D; Litvinenko, D; Lukyanchuk, V, 2017
)
0.46
"Orally dosed drugs must dissolve in the gastrointestinal (GI) tract before being absorbed through the epithelial cell membrane."( Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.
Al-Gousous, J; Amidon, GE; Amidon, GL; Greenwood, DE; Kuminek, G; Salehi, N; Sperry, DC; Waltz, NM; Ziff, RM, 2021
)
0.62
" These novel solids are potential candidates for BER solid forms with improved oral dosage design and may prompt further development."( Novel multi-component crystals of berberine with improved pharmaceutical properties.
Ban, S; Han, W; Shang, X; Wang, F; Yang, X; Zhang, G; Zhang, S, 2023
)
0.91
" Thus, the goal of this study was to develop and validate a stability-indicating high-performance thin-layer chromatography (HPTLC) method for evogliptin tartrate in bulk and tablet dosage form."( Stability-Indicating Densitometric Analysis of Evogliptin Tartrate in Bulk and Tablet Dosage Form.
Dhaneshwar, S; Kawathekar, N; Srivastava, S, 2023
)
0.91
"The proposed method has a promising application commercially for identification, routine quantitative determination, and monitoring of stability of the evogliptin tartrate in bulk and tablet dosage forms to guarantee its safety, efficacy, and quality."( Stability-Indicating Densitometric Analysis of Evogliptin Tartrate in Bulk and Tablet Dosage Form.
Dhaneshwar, S; Kawathekar, N; Srivastava, S, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
tartaric acid
tartaric acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Inner Membrane Transport7862
Glycolate and Glyoxylate Degradation II1221

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.63100.044717.8581100.0000AID485294
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency100.00000.631035.7641100.0000AID504339
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency1.94940.000214.376460.0339AID720691
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.21870.000229.305416,493.5996AID743075
gemininHomo sapiens (human)Potency16.32370.004611.374133.4983AID624296; AID624297
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
thyroid stimulating hormone receptorHomo sapiens (human)Potency1.58490.001318.074339.8107AID926; AID938
gemininHomo sapiens (human)Potency0.00520.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Phosphoinositide Phosphatase PtenHomo sapiens (human)Ki15,000.000015,000.000015,000.000015,000.0000AID977610
Chain A, Prostatic Acid PhosphataseRattus norvegicus (Norway rat)Ki1.00001.00001.00001.0000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1811Experimentally measured binding affinity data derived from PDB1999Cell, Oct-29, Volume: 99, Issue:3
Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1999Cell, Oct-29, Volume: 99, Issue:3
Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2012The Journal of biological chemistry, Jun-22, Volume: 287, Issue:26
Structural studies on molecular interactions between camel peptidoglycan recognition protein, CPGRP-S, and peptidoglycan moieties N-acetylglucosamine and N-acetylmuramic acid.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID106733Inhibition of MT-2 cell growth by 5% or less over a 72 hr time period.2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Dicaffeoyltartaric acid analogues inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at nontoxic concentrations.
AID235210Therapeutic index (ratio of CT5 to ED50).2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Dicaffeoyltartaric acid analogues inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at nontoxic concentrations.
AID106907Concentration that inhibits Human Immunodeficiency Virus Type 1 (HIV-1)-induced death of MT-2 cells1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
AID91578Inhibition of Human Immunodeficiency Virus Type 1 integrase (HIV-1 IN) in the disintegration reaction at a concentration of 25 uM1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
AID226214Inhibition of 50% of the integrase-mediated catalysis of the V1/V2 substrate2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Dicaffeoyltartaric acid analogues inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at nontoxic concentrations.
AID82726Inhibition of HIV replication by 50%.2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Dicaffeoyltartaric acid analogues inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at nontoxic concentrations.
AID226216Inhibition of 50% of the integrase-mediated catalysis of the Y-oligo substrate2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Dicaffeoyltartaric acid analogues inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at nontoxic concentrations.
AID447578Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.
AID104233Lethal dose (LD5) concentration inhibiting growth of MT-2 cells by 5%1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1993The Journal of biological chemistry, Oct-05, Volume: 268, Issue:28
Three-dimensional structure of rat acid phosphatase in complex with L(+)-tartrate.
AID1811Experimentally measured binding affinity data derived from PDB1993The Journal of biological chemistry, Oct-05, Volume: 268, Issue:28
Three-dimensional structure of rat acid phosphatase in complex with L(+)-tartrate.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,147)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990264 (23.02)18.7374
1990's182 (15.87)18.2507
2000's269 (23.45)29.6817
2010's344 (29.99)24.3611
2020's88 (7.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials19 (1.60%)5.53%
Reviews0 (0.00%)6.00%
Reviews25 (2.10%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies9 (0.76%)4.05%
Observational0 (0.00%)0.25%
Observational1 (0.08%)0.25%
Other8 (100.00%)84.16%
Other1,137 (95.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]